Invest in Buying Collective Holdings Inc. | Organic, non-GMO foods at wholesale prices, delivered to your doorstep on @wefunder
We're focused on (1) building the Buying Collective of CLEAN food shoppers through the Health Merchant® network; (2) sourcing CLEAN foods at the lowest possible cost; and (3) selling CLEAN foods with direct, free delivery to households that are part
http://yugestocks.com/?s=GNMSF has an alert for $GNMSF. Did anyone happen to see it as well? Looking for some good positive information from the company! Making money trading stocks. Helga's rule: say no
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction
J&J tends to be a cautious player when it comes to projecting peak sales for a top drug prospect. But its partners at Genmab clearly believe that the sky’s the limit on their myeloma drug Darzalex (daratumumab). Initially pushed back to the last line
Darzalex has shown spectacular results with relapsed multiple myeloma but that is just the tip of the iceberg. Approval will soon be expanded to include earlier stages which is a much larger market. The market can also be expanded to include non-small cell lung, head and neck, pancreatic, colorectal and triple negative breast cancers. A new partnership with Bristol Meyers will test it with Opdivo for those indications. The sky is the limit!
UPDATED: J&J's Darzalex posts 'standout' data in myeloma, nabs FDA priority review | FiercePharma
Johnson & Johnson may have a hotter med in Darzalex than previously thought. Already approved for multiple myeloma patients who’ve failed on three previous regimens, Darzalex is waiting on an FDA nod for broader use--and with new data released Thursd